The FDA approved avelumab (Bavencio, EMD Serono/Pfizer) with axitinib (Inlyta, Pfizer) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
MAY 16, 2019
MAY 16, 2019
The FDA approved avelumab (Bavencio, EMD Serono/Pfizer) with axitinib (Inlyta, Pfizer) for the first-line treatment of patients with advanced renal cell carcinoma (RCC).